Societal CDMO, Inc. (SCTL)

NASDAQ: SCTL · IEX Real-Time Price · USD
0.760
-0.040 (-5.00%)
Jul 5, 2022 4:30 PM EDT - Market closed

Company Description

Societal CDMO, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally.

It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services.

The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

Societal CDMO, Inc.
Country United States
Founded 2007
IPO Date Mar 7, 2014
Industry Drug Manufacturers-Specialty & Generic
Sector Health Care
Employees 185

Contact Details

Address:
1 E. Uwchlan Avenue
Exton, PA 19341
United States
Phone 770 534 8239
Website recropharma.com

Stock Details

Ticker Symbol SCTL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001588972
ISIN Number US75629F1093
SIC Code 2834

Key Executives

Name Position
J. David Enloe Jr. President, Chief Executive Officer and Director
Ryan D. Lake CPA Chief Financial Officer
Marshall Rizzo M.B.A. Senior Vice President of Operations
Richard Sidwell Ph.D. Vice President and Chief Scientific Officer
Cristin Grove Vice President of Sales
Erica Raether M.A. Vice President of People, Culture and ESG
Randall J. Mack Senior Vice President of Development
Eduardo Uribe Head of Quality of San Diego

Latest SEC Filings

Date Type Title
Jul 5, 2022 SC TO-I/A Tender offer statement by Issuer
Jul 5, 2022 4 Statement of changes in beneficial ownership of securities
Jun 30, 2022 8-K Current report
Jun 27, 2022 SC 13D General statement of acquisition of beneficial ownership
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 13, 2022 SC TO-I/A Tender offer statement by Issuer
Jun 8, 2022 8-K Current report
Jun 2, 2022 4 Statement of changes in beneficial ownership of securities
Jun 1, 2022 SC TO-I Tender offer statement by Issuer
May 20, 2022 4 Statement of changes in beneficial ownership of securities